ReviewCurrent opinion in pharmacology2020
Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance.
Review in Current opinion in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin.Biomedicines · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitors: Guarding Against Cisplatin-Associated Magnesium Wasting and Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy.Kidney international reports · 2025Article
- SGLT2 Inhibitors as a Therapeutic Option for Both Acute and Chronic Refractory Hypomagnesemia in Diabetic and Nondiabetic Patients: A Multicenter Case Series.Case reports in nephrology · 2025Article
- Magnesium biology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
- Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Magnesium in hypertension: mechanisms and clinical implications.Frontiers in physiology · 2024Review
- Case report: Two novel compound heterozygous variant ofFrontiers in genetics · 2024Article
- Magnesium depletion score and gout: insights from NHANES data.Frontiers in nutrition · 2024Article
- Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival.Clinical kidney journal · 2023Article
- Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.Heart failure reviews · 2023Review
- Home Subcutaneous Magnesium Infusion in Refractory Hypomagnesemia: A Case Report.Kidney medicine · 2023Article
- Physiology of a Forgotten Electrolyte-Magnesium Disorders.Advances in kidney disease and health · 2023Review
- Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.International journal of molecular sciences · 2022Review
- Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis.Frontiers in cardiovascular medicine · 2022Article
- Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.Frontiers in endocrinology · 2021Review
- Editorial: Cardiovascular and renal 2020: Cardiovascular protection by antidiabetic drugs: Key mechanisms and current clinical data.Current opinion in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Robust clinical data indicate that inhibitors of the sodium/glucose cotransporter 2 (SGLT2) dramatically improve clinical outcomes in diabetes, especially heart failure and progression of kidney disease. Factors that may contribute to these findings include: 1) improved glycemic control, 2) diuresis and reduced extracellular fluid volume, 3) reduced serum uric acid levels, 3) direct myocardial effects, 4) reduction in proteinuria and preservation of kidney function, and 5) correction of diabetic magnesium deficiency. Understanding the mechanisms by which SGLT2 inhibitors improve cardiovascular outcomes has the potential to improve clinical management not only of diabetes, but also of other cardiovascular disorders such as heart failure and chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.